Overseas Studies May Not Be Worth Oversight Costs, Consultants Suggest
This article was originally published in The Pink Sheet Daily
Executive Summary
Overseas clinical trials could save companies money, but consultants on a regulatory panel at the Biotechnology Industry Organization's Mid-America VentureForum in Cleveland suggested such studies might not be worth the oversight costs